Earnings Summary

Ligand Pharmaceuticals Incorporated’s revenue fell -44.22% since last year same period to $28.1Mn in the Q4 2023. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated -14.5% fall in its revenue since last 3-months.

Ligand Pharmaceuticals Incorporated’s net profit jumped 225.14% since last year same period to $18.19Mn in the Q4 2023. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated 242.18% jump in its net profits since last 3-months.

Ligand Pharmaceuticals Incorporated’s net profit margin jumped 324.36% since last year same period to 64.72% in the Q4 2023. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated 266.3% jump in its net profit margins since last 3-months.

Ligand Pharmaceuticals Incorporated’s price-to-earnings ratio after this Q4 2023 earnings stands at 23.92.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current quarter stand at 0.83 - a 25.76% jump from last quarter’s estimates.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current year stand at 0.83.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) jumped 1.47% since last year same period to 1.38 in the Q4 2023. This indicates that the Ligand Pharmaceuticals Incorporated has generated 1.47% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ligand Pharmaceuticals Incorporated’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ligand Pharmaceuticals Incorporated’s return on equity (ROE) stands at 0.08.